Ascentage Pharma Group International (NASDAQ:AAPG) Trading Up 12% – Should You Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shot up 12% on Thursday . The company traded as high as $26.84 and last traded at $26.7430. 2,246 shares changed hands during mid-day trading, a decline of 33% from the average session volume of 3,353 shares. The stock had previously closed at $23.87.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Rodman & Renshaw initiated coverage on Ascentage Pharma Group International in a research report on Tuesday, January 13th. They set a “buy” rating and a $48.00 price target for the company. Oppenheimer assumed coverage on shares of Ascentage Pharma Group International in a research report on Thursday, December 4th. They issued an “outperform” rating and a $45.00 price objective on the stock. Lucid Cap Mkts raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. Finally, BTIG Research reiterated a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a research report on Thursday, March 26th. One research analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $48.00.

Ascentage Pharma Group International Trading Down 0.3%

The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79. The stock has a 50-day simple moving average of $23.90 and a two-hundred day simple moving average of $29.48.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings data on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The firm had revenue of $24.72 million during the quarter.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Ascentage Pharma Group International during the third quarter worth approximately $96,000. ABC Arbitrage SA bought a new stake in shares of Ascentage Pharma Group International in the 3rd quarter worth approximately $204,000. Citadel Advisors LLC purchased a new stake in shares of Ascentage Pharma Group International in the 3rd quarter valued at $383,000. Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International in the 2nd quarter valued at $391,000. Finally, Tema Etfs LLC bought a new position in shares of Ascentage Pharma Group International during the 2nd quarter valued at $610,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.